Immunoprecise, Elektrofi To Pursue Low-Volume Injectable Formulation Of IPA's COVID-19 Antibody Cocktail

Elektrofi and Immunoprecise Antibodies Ltd IPA have collaborated to explore a high-concentration formulation of IPA's COVID-19 antibody cocktail, PolyTope TATX-03.
The collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting.
The parties anticipate formulating TATX-03E for stable and rapid distribution to the consumer, a drug product ideally suited to serve unmet needs for rapid deployment, field use, and higher frequency dosing for immunocompromised individuals requiring ongoing access to therapies and prophylaxis.
Related: Immunoprecise's COVID-19 Antibody Cocktail Shows Favorable Safety, Toxicity Profile.
The collaboration between Elektrofi and IPA will be supported by Elektrofi's contract with the DHA Small Business Innovation Research (SBIR) Program within the Department of Defense (DoD).
The companies will begin by conducting formulation feasibility studies followed by IND-enabling, non-clinical studies to establish safety and efficacy with the novel formulation.
Price Action: IPA shares are down 1.37% at $3.59 during the market session on the last check Monday.